Try our Advanced Search for more refined results

Xu v. FibroGen, Inc. et al

  1. January 31, 2024

    FibroGen's $28.5M Deal With 30K Investors Nears Tentative OK

    A California federal judge indicated Wednesday that he'll preliminarily sign off on a $28.5 million settlement secured for a class of approximately 30,000 FibroGen investors who accused the company of making misleading statements about the safety of its anemia drug, citing the risk of recoverability issues due to FibroGen's financial state.

  2. June 09, 2023

    FibroGen Investors Seek Sanctions For Destroyed Evidence

    FibroGen Inc. investors involved in a securities fraud class action against the biotechnology company have asked a California federal judge to grant a motion for default judgment and impose sanctions, arguing that the defendants intentionally destroyed critical evidence relevant to the case.

  3. July 18, 2022

    FibroGen Can't Dodge Securities Suit Over Anemia Drug

    FibroGen Inc. can't escape a securities fraud class action over the flop of a once-hyped anemia drug, as a California judge ruled the investors plausibly alleged that the company made misleading statements that affected the value of the company's stocks.